Pharmacological action

Combined preparation for topical treatment of psoriasis. Calcipotriol is a synthetic analogue of the active metabolite of vitamin D, inhibits proliferation of keratinocytes and accelerates their morphological differentiation.

Betamethasone - GCS, when used externally has a local anti-inflammatory, antipruritic, vasoconstrictor and immunosuppressive effects. The use of occlusive dressings increases the effect of SCS for external use, because it increases their penetration into the skin itself.


Absorption and distribution

When applied topically suction calcipotriol and betamethasone through intact skin is less than 1%. When applying the product to psoriatic plaques and under occlusive dressings absorption increases.

Because the skin is created depot medication, his elimination from the skin occurs within a few days.

Metabolism and excretion

Betamethasone biotransformiruetsya in the liver and kidneys with the formation of two drugs and sulfoefirov. Is derived from the feces and urine.


- Chronic patchy vulgar psoriasis.

Dosage regimen

Dayvobet designated adult. Ointment applied thinly to the affected skin 1 time / day.

The maximum daily dose is no more than 15 g, the maximum weekly dose is 100 g.

Duration of treatment - 4 weeks. Perhaps a re-treatment courses.

The area of application should not exceed 30% of body surface.

Side effect

Adverse effects are classified according to frequency of occurrence: the most common> 1 / 10, parts> 1 / 100 and <1> 1 / 1000 and <1> 1 / 10 000 and <1 / 1000, very rare <1 / 10 000.

Dermatological reactions: frequent - itching, rash, burning sensation, sometimes - pain, skin irritation, dermatitis, erythema, exacerbation of psoriasis, pigmentation disorders on-site application of ointment, folliculitis, rare - pustular psoriasis.

Calcipotriol may cause local skin irritation, itching, burning, sharp pain, dry skin, erythema, rash, dermatitis, eczema and exacerbation of psoriasis.

With prolonged use of topical betamethasone (dipropionate) link development Skin atrophy, telangiectasia, striae formation, folliculitis, hypertrichosis, perioral dermatitis, allergic contact dermatitis, hyperpigmentation, colloid degeneration of the skin, as well as the increased risk of generalized pustulous psoriasis, hyper-reaction and the photosensitivity, including the extremely rare cases of angioedema and edema of the face.

Systemic reactions:

In the application of calcipotriol very rare side effect is hypercalcemia and hypercalciuria.

With topical application of betamethasone link (rare but sometimes severe, especially for prolonged use, the vast surfaces and the use of occlusive dressings) - suppression of adrenocortical function, cataracts, infection, increased intraocular pressure.


- Diseases which are accompanied by violations of calcium metabolism;

- Expressed in renal and hepatic failure;

- Viral (including herpes or varicella), fungal, bacterial and parasitic skin infections, rosacea, acne rosacea, acne vulgaris, perioral dermatitis, cutaneous manifestations of tuberculosis and syphilis, skin atrophy, skin ulcers, increased fragility of vessels of skin, ichthyosis, and periproctic genital itching;

- Psoriatic erythroderma, teardrop-shaped, exfoliative, pustular psoriasis;

- Hypersensitivity to the drug's components.

Application of pregnancy and breastfeeding

Health & Safety Dayvobeta during pregnancy and lactation is not installed, so the drug may only when in the opinion of the doctor therapy with its use is required.

Application for violations of liver function

Contraindicated appointment in marked hepatic insufficiency

Application for violations of renal function

Contraindicated appointment in marked renal insufficiency


Do not apply ointment on the skin, mucous membranes and the scalp. After using the product, wash your hands.

In applying Dayvobeta in doses exceeding recommended, may develop hypercalcemia, quickly passing at lower doses or withdrawal of the drug.

Not recommended during the application Dayvobeta conduct concomitant treatment with other SCS.

Do not use the drug to large areas of skin, make up more than 30% body surface, and the folds of the skin, as well as under occlusive dressing, as This increases the likelihood of systemic absorption of GCS and the development of systemic adverse reactions.

For very long-term use of GCS for outdoor use (including Dayvobet) may develop suppression of the hypothalamic-pituitary-adrenal system with the development of reversible secondary adrenal insufficiency, or exacerbation of diabetes mellitus.

Complication of psoriasis secondary infection should be antibiotic therapy, while exacerbating the disease repeal the drug.

During treatment Dayvobetom should limit or avoid excessive exposure to natural or artificial sunlight. Application Dayvobeta with UV radiation is possible only if the potential benefit outweighs the potential risk.

Use in Pediatrics

Clinical experience with Dayvobeta in children and adolescents under the age of 18 years is missing.

Effects on ability to drive vehicles and management mechanisms

Dayvobet not affect the ability to drive motor vehicles and management mechanisms.


Symptoms: increased content of calcium in the blood, suppressing the function of the hypothalamic-pituitary-adrenal system to the development of reversible secondary adrenal insufficiency.

Treatment: removal of preparation, if necessary, carry symptomatically. In cases of chronic toxicity GCS should be lifted gradually.

Drug interaction

To date, drug interactions drug Dayvobet not described.

To the top

The drug is approved for use as a non-prescription medicines.

Terms and Conditions of storage

The product should be stored out of reach of children at or above 25 ° C. Shelf life - 2 years.

After first opening of the tube shelf life - 3 months.